Celldex Therapeutics, Inc. (CLDX): Net Income

Annual figures by period end, from SEC filings.

-$258.76M

Year ended 2025-12-31

-$300.55M

Trailing 12 months to 2026-06-30

2023-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$258.76M	n/m	2026-02-25, From 2025-01-01
2024-12-31	-$157.86M	n/m	2026-02-25, From 2024-01-01
2023-12-31	-$141.43M	n/a	2026-02-25, From 2023-01-01

Net Income at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Celldex Therapeutics, Inc. (CLDX)	2025-12-31	-$258.76M	n/m
Volitionrx Ltd (VNRX)	2025-12-31	-$23.36M	n/m
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	-$50.22M	n/m
Biomerica Inc (BMRA)	2026-05-31	-$3.77M	n/m
Anbio Biotechnology (NNNN)	2025-12-31	$6.40M	+169.9%
Aspira Women's Health Inc. (AWHL)	2025-12-31	-$12.78M	n/m
Immucell Corp (ICCC)	2025-12-31	-$1.04M	n/m
Alpha Teknova, Inc. (TKNO)	2025-12-31	-$17.26M	n/m
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	-$412.69M	n/m

Compare CLDX, VNRX, IMDX, BMRA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗